Starling Oncology, Inc. (NasdaqCM: STLN)
Health Care · Health Care Providers & Services · US
$6.81
+2.71% today · +69.6% 1Y
Starling Oncology, Inc. (NasdaqCM: STLN) operates in the Health Care Providers & Services industry within the Health Care sector. The company is valued at $675.70M and employs 641 people.
Over the last twelve months the share price has gained 69.6%, trading between 2.32 and 7.13.
Tweenvest scores Starling Oncology, Inc. across four factors: quality 35/100, value 45/100. Its strongest factor is value.
STLN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $675.70M
- Revenue (TTM)
- $587.24M
- P/E
- —
- EPS
- -0.30
- Dividend yield
- —
- Beta (5Y)
- 0.42
- 52-week high
- $7.13
- 52-week low
- $2.32
- Avg volume (3M)
- —
- Shares outstanding
- 101.92M
- Employees
- 641
- Next earnings
- —
About Starling Oncology, Inc.
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
- ISIN
- US68236X1000
- Founded
- 2007
- Listed since
- Aug 4, 2026
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Health Care Providers & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PT Metro Healthcare Indonesia TbkIDX: CARE | $702.39M | Rp378.00 | +1.61% |
| Shanghai Labway Clinical Laboratory Co., LtdSZSE: 301060 | $700.88M | CN¥11.78 | -2.00% |
| Bright Eye Hospital Group Co., Ltd.SZSE: 301239 | $696.30M | CN¥31.33 | -2.03% |
| Middle East Healthcare CompanySASE: 4009 | $678.06M | SR27.66 | -1.98% |
| Kovai Medical Center and Hospital LimitedBSE: 523323 | $664.77M | Rs5,879.70 | -2.03% |
| Nephrocare Health Services LimitedNSEI: NEPHROPLUS | $640.46M | Rs616.40 | -5.02% |
| SALUS, Ljubljana, d. d.LJSE: SALR | $639.61M | €69.50 | -1.42% |
| Luyan Pharma Co.,Ltd.SZSE: 002788 | $621.22M | CN¥10.71 | -0.46% |
Figures last refreshed Oct 11, 2026.